hookipa
pharma
immunotherapy
cancers
demonstrates
high
immunogenicity
according
peer
reviewed
article
peer
reviewed
article
oncoimmunology
demonstrates
promising
preclinical
results
novel
cancer
therapy
targeting
human
papillomavirus
hpv
estimated
cause
approximately
worldwide
cancer
burden
new
york
vienna
austria
globe
newswire
hookipa
pharma
nasdaq
hook
hookipa
company
developing
new
class
immunotherapeutics
targeting
infectious
diseases
cancers
based
proprietary
arenavirus
platform
today
announced
publication
peer
reviewed
open
access
journal
oncoimmunology
paper
arenavirus
immunotherapy
human
papillomavirus
cancers
currently
clinical
trials
paper
shows
systemically
administered
leads
induction
robust
systemic
cytotoxic
cell
response
directed
proteins
tumor
infiltration
specific
cytotoxic
cells
significantly
delayed
tumor
growth
complete
tumor
clearance
accompanied
prolonged
survival
mice
cleared
tumors
administration
developed
protection
demonstrated
rejection
tumors
furthermore
combination
checkpoint
inhibitor
increased
efficacy
treated
mice
clearing
established
tumors
one
hookipa
lead
oncology
candidates
targets
based
company
replicating
lcmv
arenaviral
vector
platform
currently
phase
clinical
trials
cancers
alone
combination
approved
checkpoint
inhibitor
cancers
especially
head
neck
cancers
remain
significant
health
concern
curative
therapies
currently
available
pleased
results
suggest
program
promising
therapy
cancers
said
igor
matushansky
md
phd
hookipa
chief
medical
officer
global
head
research
development
human
papillomavirus
hpv
estimated
cause
worldwide
burden
cancers
includes
approximately
cases
cervical
head
neck
vaginal
anal
cancers
majority
cancers
caused
hpv
serotype
infections
hpv
cleared
body
lasting
consequences
however
cases
hpv
dna
becomes
integrated
chromosomal
dna
host
cells
take
dna
express
hpv
proteins
uptake
potentially
lead
cancer
since
expression
proteins
leads
alterations
cell
cycle
control
turn
predisposes
cells
become
cancerous
publication
lymphocytic
choriomeningitis
vaccines
active
immunotherapy
cancer
available
online
oncoimmunology
hookipa
hookipa
pharma
nasdaq
hook
clinical
stage
biopharmaceutical
company
developing
new
class
immunotherapeutics
targeting
infectious
diseases
cancers
based
proprietary
arenavirus
platform
reprograms
body
immune
system
hookipa
proprietary
technologies
replicating
induce
robust
cells
antibodies
hookipa
viral
vectors
target
antigen
presenting
cells
vivo
activate
immune
system
technologies
enable
repeat
administration
augment
refresh
immune
responses
monotherapy
replicating
arenavirus
technology
potential
induce
cell
response
levels
previously
achieved
approaches
hookipa
prophylactic
cytomegalovirus
cmv
vaccine
candidate
currently
phase
clinical
trial
patients
awaiting
kidney
transplantation
expand
infectious
disease
portfolio
hookipa
entered
collaboration
licensing
agreement
gilead
sciences
research
functional
cures
hiv
chronic
hepatitis
b
infections
addition
hookipa
building
proprietary
pipeline
targeting
virally
mediated
cancer
antigens
antigens
lead
replicating
arenavirus
oncology
product
candidates
development
treatment
human
papilloma
virus
cancers
phase
clinical
trial
initiated
december
ind
application
cleared
fda
june
find
hookipa
online
hookipa
forward
looking
statements
certain
statements
set
forth
press
release
constitute
statements
within
meaning
private
securities
litigation
reform
act
amended
statements
identified
terms
believes
expects
plans
potential
would
similar
expressions
negative
terms
statements
involve
substantial
risks
uncertainties
could
cause
hookipa
research
clinical
development
programs
future
results
performance
achievements
differ
significantly
expressed
implied
statements
risks
uncertainties
include
among
others
uncertainties
inherent
drug
development
process
including
hookipa
programs
early
stage
development
process
designing
conducting
preclinical
clinical
trials
regulatory
approval
processes
timing
regulatory
filings
challenges
associated
manufacturing
drug
products
hookipa
ability
successfully
establish
protect
defend
intellectual
property
risks
relating
business
interruptions
resulting
coronavirus
disease
outbreak
similar
public
health
crises
impact
enrollment
patients
timing
clinical
results
programs
matters
could
affect
sufficiency
existing
cash
fund
operations
hookipa
ability
achieve
milestones
agreement
gilead
hookipa
undertakes
obligation
update
revise
statements
description
risks
uncertainties
could
cause
actual
results
differ
expressed
statements
well
risks
relating
business
company
general
see
hookipa
quarterly
report
form
quarter
ended
june
available
security
exchange
commission
website
hookipa
website
investors
others
note
announce
material
financial
information
investors
using
investor
relations
website
https
sec
filings
press
releases
public
conference
calls
webcasts
use
channels
well
social
media
communicate
members
public
company
services
issues
possible
information
post
social
media
could
deemed
material
information
therefore
encourage
investors
media
others
interested
company
review
information
post
social
media
channels
listed
investor
relations
website
